 AUSTIN, Texas , Dec. 7, 2022 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and tumor-informed molecular residual disease MRD test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium SABCS in San Antonio, Texas. Natera will present two posters from the LEADER and I-SPY 2 clinical trials in HR, HER2- breast cancer highlighting Signateras ability to detect recurrence and facilitate treatment response monitoring. 